Jilin reports China’s second COVID-19 patient death in latest outbreak

Northeast China’s Jilin Province reported one death caused by COVID-19 on Monday, the second coronavirus fatality after North China’s Hebei Province reported its first in mid-January in the latest outbreak.

It was eight months since China last reported COVID-19 death in May 17.

The new death in Tonghua, Jilin, was an 87-year-old patient with a variety of underlying diseases.

State media China Central Television reported on Tuesday that the patient had close contact with an asymptomatic carrier and was diagnosed as a COVID-19 critical-type patient after a positive nucleic acid test.

After joint consultation between national and provincial medical expert groups, the patient’s condition improved after treatment, but due to underlying heart disease and virus infection, the patient developed rapid arrhythmia and drop in blood pressure, and suffered respiratory and cardiac arrest on Monday.

The province has recently seen a resurgence in COVID-19 cases. On Monday, it recorded another seven confirmed cases, all of whom were initially asymptomatic carriers, 15 new asymptomatic patients and one death in the city of Tonghua.

Also, the province reported one patient was discharged from hospital after being cured in the city of Changchun.

Jilin has reported 280 confirmed cases and 67 asymptomatic patients amid the recent outbreak as of the end of Monday.

Among the confirmed cases, 202 were found in Tonghua, 72 in Changchun and four in Songyuan. Among the silent carriers, 58 were recorded in Tonghua and nine in Changchun.

The cases have been transferred to designated medical institutions for quarantine, observation and treatment.

Close contacts, sub-close contacts and ordinary contacts of the above-mentioned cases have been tracked and investigated, control measures have been put in place, and disinfection of their living and working places have been carried out.

Photo: VCG

Comments

No comments yet. Why don’t you start the discussion?

Leave a Reply

Your email address will not be published. Required fields are marked *